source
- Merck wins FDA nod for first oral PCSK9 inhibitor, Lipfendra, to treat high LDL cholesterolMerck announced that the U.S. Food and Drug Administration has approved its once-daily oral PCSK9 inhibitor, enlicitide, marketed as Lipfendra, for adults with elevated LDL cholesterol. The drug i…
- Merck secures US approval for the first oral PCSK9 cholesterol-lowering pill, edging out AstraZenecaMerck has received the United States regulatory clearance for an oral PCSK9 inhibitor, marking the first time a pill of this class has been approved for cholesterol management. The approval comes…